PPARA and type 2 diabetes mellitus: PPAR activators have provided significant benefit in patients with primary hypertriglyceridemia (i.e., fibrates and omega-3 fatty acids, both PPAR-α agonists), as well as in cases of mixed hyperlipidemias with raised TGs and low HDL-C; conversely, PPAR-γ activators have become choice drugs in T2D.